Diseases

Novo Nordisk rebrands to Novo and drops the dual name as obesity shifts to a consumer market. What changes, what is left behind, and what the 21 September Capital Markets Day must deliver. #SyenzaNews #NovoNordisk #MarketAccess #Obesity

Definium Therapeutics' DT120 ODT met its primary endpoint in the Phase 3 Panorama trial, delivering a 5.1-point placebo-adjusted improvement on the HAM-A anxiety scale. #SyenzaNews #GAD #MentalHealth #MarketAccess

The FDA's landmark hearing on psychedelic medicines drew 80 speakers and 1,800 registrants, and the market access message was clear: approval is not access, and reimbursement is the binding constraint. #SyenzaNews #MarketAccess #Psychedelics #HealthPolicy

South Africa's High Court has kept the semaglutide compounding ban in place, dismissing iDexis's appeal as an 'abuse of process' while SAHPRA and SAPC finish their investigations. #SyenzaNews #MarketAccess #Pharma

Enhertu's DESTINY-Lung04 trial cut the risk of progression versus chemo-immunotherapy in first-line HER2-mutant NSCLC, but an immature overall-survival trend and a 20.8% ILD rate complicate the path to a first-line label. #SyenzaNews #Oncology #NSCLC #MarketAccess

Every NCCN academic cancer center now reports a shortage of at least one anticancer medicine, led by ifosfamide (94%) and carboplatin (71%). Pharmacy directors say three years of policy have not moved the problem. #SyenzaNews #DrugShortages #Oncology #MarketAccess

NICE has opened consultation on draft guidance that does not recommend lenacapavir for HIV PrEP, finding the six-monthly injection is not value for money for the NHS in England. #SyenzaNews #HTA #HIV #PrEP #MarketAccess

Real-world UK data presented at ERS 2026 link semaglutide to fewer asthma attacks and COPD exacerbations. The indication stays metabolic, but the signal raises a real question for value and access teams. #SyenzaNews #MarketAccess #GLP1 #Respiratory

Camizestrant (Etcamah) gains accelerated FDA approval for ESR1-mutated advanced breast cancer, with median progression-free survival of 16 months versus 9.2 months in SERENA-6. #SyenzaNews #BreastCancer #FDA #Oncology

South Africa has initiated 55,123 people on twice-yearly lenacapavir PrEP in the programme's first 94 days. Demand is strongest in Gauteng and KwaZulu-Natal; branded supply, second-dose retention and the 2027 generic tender are the real constraints. #SyenzaNews #HIVPrevention #Lenacapavir #MarketAccess

Novartis and The Max Foundation mark 25 years of partnership that has delivered cancer treatment to more than 100,000 patients across 71 LMICs. The next test is whether the model can carry a broader oncology portfolio and transition to country funding. #SyenzaNews #MarketAccess #GlobalHealth

An Insilico Medicine phase 2a trial found six proteomic aging clocks all detected lower biological age in patients treated with rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis. #SyenzaNews #Proteomics #AgingClocks #DrugDiscovery #IPF